Study: Rivaroxaban is effective, but increases bleeding risk

02/8/2013 | Forbes · MedPage Today (free registration)

The anticoagulant rivaroxaban was effective at preventing venous thromboembolism in patients with acute illnesses, but it was associated with a significant increase in bleeding risk, according to a study published in the New England Journal of Medicine. The study compared rivaroxaban with enoxaparin.

View Full Article in:

Forbes · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI